PepGen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - PEPG

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to allegations of misleading statements related to the company's lead product candidate, PGN-EDO51, and its clinical study [1][2]. Group 1: Allegations and Class Action Details - The class period for the allegations is from March 7, 2024, to March 3, 2025 [1]. - Allegations include that PGN-EDO51 was less effective and safe than claimed, and that the CONNECT2 study was dangerous or deficient for FDA approval [1]. - The lawsuit suggests that PepGen may halt the CONNECT2 study, and that the prospects for PGN-EDO51 were overstated [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 8, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].